On March 13, 2006 Analytical Spectral Device, Inc. ("ASD") served upon CDEX a patent infringement lawsuit in the District Court of Colorado alleging patent infringement by CDEX of U.S. Patent No. 6,771,369 (the "'369 patent"). CDEX filed an Answer with the court on May 1, 2006 denying ASD's claims for patent infringement and setting forth various affirmative defenses and counterclaims, including non-infringement, invalidity, and unenforceability of the `369 patent. A scheduling conference was held on May 23, 2006 in which the Magistrate Judge entered a tentative case schedule. The parties agreed to terms of settlement of the litigation during a settlement conference held by the Magistrate Judge on September 1, 2006. The parties are currently in the process of formalizing the settlement agreement that will form the basis of an Order to Dismiss. The dismissal paper is to be submitted to the Court on or before October 2, 2006. The terms and conditions upon which the settlement agreement is based are to be kept confidential. Trial is currently scheduled for the fall of 2007.
CDEX Granted Notice of Allowance for U.S. Patent Application Covering Identification and Determination of Chemical Substances Using Enhanced Photoemission Spectroscopy
July 31, 2014: 08:30 AM ET
CDEX Inc. (OTCBB: CDEX) (OTCQB: CDEX), a pioneering developer, manufacturer and distributor of patented, real-time chemical detection and validation technologies for the healthcare and security markets, today announced that the U.S. Patent and Trademark Office has granted a Notice of Allowance for U.S. Patent Application No. 13/673,270 with claims that cover methods for identifying and determining unknown substances using enhanced photoemission spectroscopy ("EPS"). Jeffrey Brumfield, CDEX Chairman and CEO, stated, "Issuance of this patent will further strengthen and extend what we believe is CDEX's leading position as a true innovator in our industry. Moreover, these claims provide significant protection for our proprietary EPS technology, constitute yet another stamp of approval for the validity and innovative aspects of our proprietary products currently being commercialized, and empower us with crucial competitive distinction in the global marketplace." This new patent joins previously issued U.S. patents, which comprise a platform portfolio of technologies, systems and methodologies underlying CDEX's first commercial innovations: The ValiMed™ System, which provides real-time validation of drugs or the detection of foreign materials; the ID2™ Meth Scanner, a hand-held, battery-operated scanner for detecting all forms of methamphetamines; and the Pocket ID2™, which provides a more portable and easily concealed device for convenience and security purposes use in law enforcement, prisons, homeland security, border patrol, port authorities and other applicable environments. About CDEX Inc. Headquartered in Tucson, Arizona, CDEX is engaged in pioneering technological advancements in the field of chemical and medication detection and validation for the healthcare and security markets. The Company's proprietary solutions are based on its patented Enhanced Photoemission Spectroscopy technology for substance verification, authentication and identification; and include the ValiMed™ Medication Validation System product line marketed to healthcare markets worldwide for use in combatting diversion of controlled substances and narcotics, as well as compounded liquid pharmaceuticals to help ensure patient safety, and the ID2™ product line marketed to the global security market for use in detecting illegal or illicit drugs in difficult-to-monitor, critical environments. For more information, please visit www.cdex-inc.com. Forward-Looking Statements This news release may contain forward-looking statements. Forward-looking statements are indicated by words such as "expects," "intends," "anticipates," "believes," "forecasts," "plans" and similar expressions. These forward looking statements are based on our current expectations and actual results could differ materially. Our ability to achieve the results anticipated in such forward-looking statements is subject to risks and uncertainties, including, without limitation, our ability to successfully centralize and consolidate various support functions, operating results, market acceptance of our solutions, strong brand recognition and other risks detailed from time to time in our reports filed with the Securities and Exchange Commission. These forward-looking statements are made in accordance with "safe harbor" provided by the Private Securities Litigation Reform Act of 1995 and no assurance can be given that the future results that are the subject of such forward-looking statements will be achieved. The Company undertakes no obligation to publicly update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise.
Agreed. The prop g4 claims to use a Raman laser to produced the claimed three way examination of substances. The ASD suit and payments may be repeated by others who claim similar methods regardless of the cdex patent. But hey no worries there is a flock of suckers according to one tout ready to throw money at any problem when it comes.
News 
Market Data 
Discover 
